Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients

MEN1611 is a novel orally bioavailable PI3K inhibitor currently in clinical development for patients with HER2‐positive (HER2+) PI3KCA mutated advanced/metastatic breast cancer (BC) in combination with trastuzumab (TZB). In this work, a translational model‐based approach to determine the minimum tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosca, Elena M., Borella, Elisa, Piana, Chiara, Bouchene, Salim, Merlino, Giuseppe, Fiascarelli, Alessio, Mazzei, Paolo, Magni, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681519/
https://www.ncbi.nlm.nih.gov/pubmed/36793223
http://dx.doi.org/10.1002/psp4.12910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681519/
https://www.ncbi.nlm.nih.gov/pubmed/36793223
http://dx.doi.org/10.1002/psp4.12910

Ejemplares similares